BPC-157 · DOSSIER

BPC-157

Body Protection Compound 157 · PL 14736 · Peptide · 15 AS
LEGAL DE · NOT APPROVEDEVIDENCE · PRECLINICAL3 STUDIESWADA · S2
SUMMARY

In rodent studies, tendons, muscle and gut lining healed faster.

FIG.01 — SIGNAL CHAIN
GEPPPGKPADDAGLV · ~1419.5 Da
FOR BEGINNERS

Simply explained: what is BPC-157?

No jargon — in four pictures.

A short chain

BPC-157 is made of 15 tiny protein building blocks — like a short word made of letters.

MECHANISM ONLY
Modelled on the body

It's modelled on a substance the stomach itself produces to protect itself.

MECHANISM ONLY
A repair signal

In animal studies it sped up tissue healing, acting like a repair signal.

ANIMAL MODELS ONLY
Unproven in humans

Whether this also works in humans has not been proven.

UNPROVEN IN HUMANS
EVIDENCE LEVELSPROVEN IN HUMANSANIMAL MODELS ONLYMECHANISM ONLYUNPROVEN IN HUMANS
01

What it does in the body

Findings, each with its evidence level — animal data kept visibly apart from what's unproven in humans.

Faster tissue repair

In rodent studies, tendons, muscle and gut lining healed faster.

ANIMAL MODELS ONLY
Gut protection

Protected the gastrointestinal lining from damage in animal models.

ANIMAL MODELS ONLY
New blood vessels

Promotes the formation of new blood vessels — important for supplying healing tissue.

MECHANISM ONLY
Unproven in humans

There are no controlled human trials — effects in humans are not established.

UNPROVEN IN HUMANS
02

Mechanism of action

What BPC-157 does in the body — step by step.

BPC-157 · the small peptide
Signals "repair, please"
Attracts helper cells
Protects cells
Tissue heals faster
New blood vessels form
A SIMPLIFIED PICTUREMostly shown in animal studies so far — not proven in humans.
01

BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of a human gastric juice protein.

02

In preclinical studies, interactions with the NO system (nitric oxide signalling pathway) and with the EGR1 and VEGFR2 receptor pathways have been described, which may mediate angiogenic and cytoprotective effects.

03

The precise mechanisms of action in humans have not been conclusively established.

03

Research status

How far along is the evidence?

PRECLINICALEARLY CLINICAL STUDIESCLINICALLY ESTABLISHED
BPC-157 has been studied predominantly in animal models (rodents), particularly in the context of gastrointestinal lesions, tendon and muscle tissue, and wound healing.
BPC-157 has been studied predominantly in animal models (rodents), particularly in the context of gastrointestinal lesions, tendon and muscle tissue, and wound healing.
In these preclinical models, signs of accelerated tissue regeneration and gastroprotective effects were described.
Controlled human trials are largely lacking; the substance is not in active Phase II/III clinical programmes.
A Phase II study of the oral form (PL 14736) in ulcerative colitis was discontinued; results were not conclusively published.
04

Known risks

Without human data, safety statements are limited. What is known:

01
No controlled human studies — safety profile in humans not established
02
Potential interactions with the coagulation system (described in animal models)
03
Unknown long-term consequences of repeated use
04
Product quality cannot be verified from unapproved sources (contaminants, incorrect concentrations)
05
Legal risk: possession and import may be punishable
05

Cited studies

Chronological — links lead to the source.

2015
Pentadecapeptide BPC 157 reduces bleeding and thrombocytopenia after amputation in rats treated with heparin, warfarin, l-NAME and l-arginine
PubMed 26302668 →
2018
BPC 157 and Standard Angiogenic Growth Factors: Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle, and Bone Healing
PubMed 30026641 →
2021
Stable gastric pentadecapeptide BPC 157 in clinical trials as a means of treatment for both IBD and IBS – What is the current state?
PubMed 33577897 →
06

Frequently asked questions

What is BPC-157?+

BPC-157 is a synthetic pentadecapeptide derived from a partial sequence of a human gastric juice protein.

What type of peptide is BPC-157?+

BPC-157 belongs to the BPC class.

What is BPC-157 used for?+

In research, BPC-157 has primarily been investigated in the context of: Recovery, Immunomodulation. These are research findings (evidence: preclinical), not proven benefits in humans and not a usage recommendation.

Is BPC-157 legal in Germany?+

BPC-157 is not approved as a medicine in Germany. Obtaining it outside clinical studies is legally problematic.

Is BPC-157 FDA-approved / legal in the US?+

No. BPC-157 is not FDA-approved as a drug in the US; it is mostly sold as a research chemical and not for human consumption.

Is BPC-157 legal in Canada?+

No. BPC-157 is not authorized by Health Canada and not intended for human consumption.

Where can I buy BPC-157?+

Peptica sells nothing and names no sources. BPC-157 is "not approved" in Germany; obtaining unapproved substances outside clinical studies is illegal and carries quality and safety risks.

What is the dosage of BPC-157?+

Peptica publishes no dosing. There are no approved dosing guidelines for BPC-157; figures circulating online stem from animal studies or anecdote, not from validated human protocols. This is not medical advice.

Is BPC-157 banned in sport (WADA)?+

Yes. BPC-157 is on the WADA Prohibited List and is therefore banned in competitive sport.

What are the known risks of BPC-157?+

Documented risks include: No controlled human studies — safety profile in humans not established; Potential interactions with the coagulation system (described in animal models). This is not a complete safety assessment and not medical advice — see the risks section for the full list.

How well researched is BPC-157?+

The evidence is classified as “preclinical”. 3 studies are cited on this page.

What is the molecular weight of BPC-157?+

BPC-157 has a molar mass of about 1419.5 Da.

Which peptides are related to BPC-157?+

Closely related entries: TB-500. A direct side-by-side comparison is available via the compare function.

07

Dossier

Legal · Structure · Sources.

LEGAL STATUS BY REGION
Germanynot approved

Since 2022, BPC-157 has been on the WADA Prohibited List (section S2: peptide hormones, growth factors and related substances). It is not approved as a medicine in the EU, Germany, Austria or Switzerland. Importing it as a so-called research chemical is a legal grey area and may fall under the German Medicines Act (AMG). Conservative assessment: not to be obtained.

Legal status varies by country and can change. This is not legal advice.

STRUCTURE & MOLECULE
H₂NGEPPPGKPADDAGLVCOOH
15
AMINO ACIDS
~1419.5
MOL. WEIGHT (Da)
Very short
HALF-LIFE
SOURCES & EXTERNAL DATABASES

Methodology: Peptica compiles publicly available studies and regulatory information and assigns each statement an evidence level. Not medical advice. No warranty.

RELATED PEPTIDES & FURTHER READING
08

Community notes

Note: These posts are user opinions and not medical advice. Posts containing dosages, therapeutic claims or purchase recommendations are removed. All entries are manually reviewed before publication.
This page is intended solely for factual, scientifically oriented information. No medical advice · no dosage or usage recommendations · no claims of efficacy · no substitute for medical consultation. Peptica sells no substances. Partner links are marked as advertising; Peptica may earn a commission. © 2026 Peptica · Issue 01